Amgen's Ofman On Value-Based Contracts And Reimbursement Challenges

Amgen has negotiated 75 value-based contracts – agreements that SVP Josh Ofman sees as one area where biopharma and payer views are aligned. However, tension between the two sides remains high in pricing and reimbursement negotiations when it comes to rebates and other issues.

Customer Value concept on the gearwheels, 3D rendering

Amgen Inc. Senior Vice President for Global Value, Access and Policy Josh Ofman has participated in the negotiation of value-based contracts for the company's portfolio of biologics and sees the agreements as one area where both sides are optimistic about putting an appropriate value on innovative medicines.

However, Ofman said in an interview with Scrip during the BIO International Convention in June that there are many challenges...

More from Drug Pricing

More from Scrip